Cubist Systematic Strategies’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$4.89M Sell
58,300
-161,600
-73% -$13.3M 0.02% 977
2025
Q2
$17.4M Buy
219,900
+69,100
+46% +$5.49M 0.08% 345
2025
Q1
$13.5M Buy
150,800
+125,700
+501% +$11.7M 0.08% 348
2024
Q4
$2.5M Buy
25,100
+15,900
+173% +$1.64M 0.02% 1228
2024
Q3
$1.04M Sell
9,200
-35,900
-80% -$4.27M 0.01% 1810
2024
Q2
$5.58M Sell
45,100
-6,900
-13% -$889K 0.04% 714
2024
Q1
$6.86M Buy
52,000
+21,600
+71% +$2.66M 0.04% 755
2023
Q4
$3.31M Sell
30,400
-131,100
-81% -$13.6M 0.02% 1126
2023
Q3
$16.6M Buy
161,500
+6,000
+4% +$647K 0.12% 169
2023
Q2
$17.9M Sell
155,500
-39,200
-20% -$4.45M 0.12% 154
2023
Q1
$20.7M Sell
194,700
-52,900
-21% -$5.71M 0.13% 146
2022
Q4
$27.5M Sell
247,600
-56,800
-19% -$5.81M 0.16% 62
2022
Q3
$26.2M Buy
304,400
+22,900
+8% +$2.04M 0.15% 88
2022
Q2
$25.7M Buy
+281,500
New +$25M 0.16% 70

Other funds holding MRK

Cubist Systematic Strategies's MRK Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Merck (MRK) stake by 10,315% in Q3 2025, buying an estimated $37.4M and bringing the position to 458,259 shares worth $38.5M. The position accounts for 0.18% of the portfolio, ranked #114.

Cubist Systematic Strategies first reported a position in MRK in Q2 2014 and has held it in 43 quarters since. The position peaked at $40.7M in Q3 2024. 3,309 funds tracked by Wall St. Rank hold MRK as of Q3 2025.

  • Cubist Systematic Strategies held 458,259 shares of Merck worth $38.5M as of Q3 2025.
  • Cubist Systematic Strategies bought 453,859 Merck shares in Q3 2025, an estimated $37.4M.
  • Merck made up 0.18% of Cubist Systematic Strategies's portfolio in Q3 2025, its #114 holding.
  • Cubist Systematic Strategies first reported a position in Merck in Q2 2014 and has held it in 43 quarters since.
  • Cubist Systematic Strategies's Merck position peaked at $40.7M in Q3 2024.
  • 3,309 funds tracked by Wall St. Rank held Merck as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.